Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells

Kyriakos P. Papadopoulos, Charles S. Hesdorffer, Nicole Suciu-Foca, Hanina Hibshoosh, Paul E. Harris

Research output: Contribution to journalArticle

Abstract

To broaden the clinical applicability of peptide-based immunotherapy in breast cancer, there is a need to identify further tumor-associated peptide epitopes that are specific for HLA alleles, in addition to HLA-A2. The HLA- B44 haplotype is one of the most common HLA-B haplotypes, occurring in 10-20% of the population. We performed the structural characterization of HLA class I-bound self-peptides presented by a human breast cancer cell line with a HLA-A68, A32, B40, B44 haplotype, to identify potential tumor-specific antigens. Of 13 sequenced peptides, 1 peptide had the HLA-A68 peptide binding motif and 12 peptides had the HLA-B40, B44 peptide binding motif. One of the latter peptides, FEVRVCACPG, shared 100% homology to residues 270-279 of wild-type P53 protein. Our study, thus, provides direct evidence for the natural processing and presentation of p53 epitope 270-279 by HLA-B40, B44- bearing human breast tumor cells. Epitopes spanning this region of P53 may have potential use for immunotherapy in patients expressing HLA-A2 and -B44 supertypes.

Original languageEnglish (US)
Pages (from-to)2089-2093
Number of pages5
JournalClinical Cancer Research
Volume5
Issue number8
StatePublished - Aug 1999
Externally publishedYes

Fingerprint

HLA-B Antigens
Haplotypes
Epitopes
HLA-B44 Antigen
Breast Neoplasms
Peptides
HLA-B40 Antigen
HLA-A2 Antigen
Immunotherapy
Neoplasm Antigens
Alleles
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Papadopoulos, K. P., Hesdorffer, C. S., Suciu-Foca, N., Hibshoosh, H., & Harris, P. E. (1999). Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells. Clinical Cancer Research, 5(8), 2089-2093.

Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells. / Papadopoulos, Kyriakos P.; Hesdorffer, Charles S.; Suciu-Foca, Nicole; Hibshoosh, Hanina; Harris, Paul E.

In: Clinical Cancer Research, Vol. 5, No. 8, 08.1999, p. 2089-2093.

Research output: Contribution to journalArticle

Papadopoulos, KP, Hesdorffer, CS, Suciu-Foca, N, Hibshoosh, H & Harris, PE 1999, 'Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells', Clinical Cancer Research, vol. 5, no. 8, pp. 2089-2093.
Papadopoulos KP, Hesdorffer CS, Suciu-Foca N, Hibshoosh H, Harris PE. Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells. Clinical Cancer Research. 1999 Aug;5(8):2089-2093.
Papadopoulos, Kyriakos P. ; Hesdorffer, Charles S. ; Suciu-Foca, Nicole ; Hibshoosh, Hanina ; Harris, Paul E. / Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 8. pp. 2089-2093.
@article{c78bc43e52a4408c832a481d8f70ecf3,
title = "Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells",
abstract = "To broaden the clinical applicability of peptide-based immunotherapy in breast cancer, there is a need to identify further tumor-associated peptide epitopes that are specific for HLA alleles, in addition to HLA-A2. The HLA- B44 haplotype is one of the most common HLA-B haplotypes, occurring in 10-20{\%} of the population. We performed the structural characterization of HLA class I-bound self-peptides presented by a human breast cancer cell line with a HLA-A68, A32, B40, B44 haplotype, to identify potential tumor-specific antigens. Of 13 sequenced peptides, 1 peptide had the HLA-A68 peptide binding motif and 12 peptides had the HLA-B40, B44 peptide binding motif. One of the latter peptides, FEVRVCACPG, shared 100{\%} homology to residues 270-279 of wild-type P53 protein. Our study, thus, provides direct evidence for the natural processing and presentation of p53 epitope 270-279 by HLA-B40, B44- bearing human breast tumor cells. Epitopes spanning this region of P53 may have potential use for immunotherapy in patients expressing HLA-A2 and -B44 supertypes.",
author = "Papadopoulos, {Kyriakos P.} and Hesdorffer, {Charles S.} and Nicole Suciu-Foca and Hanina Hibshoosh and Harris, {Paul E.}",
year = "1999",
month = "8",
language = "English (US)",
volume = "5",
pages = "2089--2093",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells

AU - Papadopoulos, Kyriakos P.

AU - Hesdorffer, Charles S.

AU - Suciu-Foca, Nicole

AU - Hibshoosh, Hanina

AU - Harris, Paul E.

PY - 1999/8

Y1 - 1999/8

N2 - To broaden the clinical applicability of peptide-based immunotherapy in breast cancer, there is a need to identify further tumor-associated peptide epitopes that are specific for HLA alleles, in addition to HLA-A2. The HLA- B44 haplotype is one of the most common HLA-B haplotypes, occurring in 10-20% of the population. We performed the structural characterization of HLA class I-bound self-peptides presented by a human breast cancer cell line with a HLA-A68, A32, B40, B44 haplotype, to identify potential tumor-specific antigens. Of 13 sequenced peptides, 1 peptide had the HLA-A68 peptide binding motif and 12 peptides had the HLA-B40, B44 peptide binding motif. One of the latter peptides, FEVRVCACPG, shared 100% homology to residues 270-279 of wild-type P53 protein. Our study, thus, provides direct evidence for the natural processing and presentation of p53 epitope 270-279 by HLA-B40, B44- bearing human breast tumor cells. Epitopes spanning this region of P53 may have potential use for immunotherapy in patients expressing HLA-A2 and -B44 supertypes.

AB - To broaden the clinical applicability of peptide-based immunotherapy in breast cancer, there is a need to identify further tumor-associated peptide epitopes that are specific for HLA alleles, in addition to HLA-A2. The HLA- B44 haplotype is one of the most common HLA-B haplotypes, occurring in 10-20% of the population. We performed the structural characterization of HLA class I-bound self-peptides presented by a human breast cancer cell line with a HLA-A68, A32, B40, B44 haplotype, to identify potential tumor-specific antigens. Of 13 sequenced peptides, 1 peptide had the HLA-A68 peptide binding motif and 12 peptides had the HLA-B40, B44 peptide binding motif. One of the latter peptides, FEVRVCACPG, shared 100% homology to residues 270-279 of wild-type P53 protein. Our study, thus, provides direct evidence for the natural processing and presentation of p53 epitope 270-279 by HLA-B40, B44- bearing human breast tumor cells. Epitopes spanning this region of P53 may have potential use for immunotherapy in patients expressing HLA-A2 and -B44 supertypes.

UR - http://www.scopus.com/inward/record.url?scp=0032771492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032771492&partnerID=8YFLogxK

M3 - Article

C2 - 10473091

AN - SCOPUS:0032771492

VL - 5

SP - 2089

EP - 2093

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -